Last reviewed · How we verify
NCT03187912
Accelerated Corneal Cross-linking With Different Riboflavin Solutions
Phase 3 trial testing Riboflavin in Keratoconus in 60 participants. Completed in 30 March 2020.
30 March 2020
Quick facts
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 19 September 2016 |
| Primary completion | 30 March 2020 |
| Estimated completion | 30 March 2020 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Riboflavin (RIBOFLAVIN) — full drug profile →
Conditions studied
- Keratoconus — all drugs for Keratoconus →
Sponsor
Medical University of Vienna
Who can join
Adults 18 to 99, any sex, with Keratoconus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Following the Bunsen-Roscoe law, accelerated cross-linking protocols with higher irradiation intensities and shorter irradiation times have been introduced. In addition, new riboflavin solutions with HPMC (hydroxylpropyl methylcellulose) instead of dextran found its way into CXL-treatment. The aim of this trial is to evaluate clinical outcomes in an accelerated corneal collagen cross-linking protocol with different riboflavin solutions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03187912
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Riboflavin
Trials testing the same drug.
- NCT05907850 — Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes · EARLY_PHASE1 · completed
- NCT05803811 — Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults · NA · completed
- NCT04232800 — Riboflavin for Glutamate Reduction in Alcohol Withdrawal · Phase 2 · unknown
- NCT03432572 — Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets · EARLY_PHASE1 · completed
- NCT03151096 — Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the M · NA · terminated
Other recruiting trials for Keratoconus
Currently open trials in the same condition.
- NCT07372911 — PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus · NA · recruiting
- NCT07461129 — Electrophysiological Changes in Cases of Different Stages of Keratoconus · active not recruiting
- NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
- NCT05516004 — Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning · Phase 2 · recruiting
- NCT06798779 — Predicting Manifest Astigmatism in Keratoconus Patients. · active not recruiting
Other Medical University of Vienna trials
Trials by the same sponsor.
- NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
- NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
- NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03187912 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
- Last refreshed: 3 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03187912.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing